Clinical trial · Interventional
The Role of L-arginine in Polycystic Ovary Syndrome
The Safety and Efficacy of L-arginine in Patients With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PCOS patients meeting the trial criteria were enrolled from the Shanghai 10th People's Hospital. The contents of this study were introduced to them, and they were invited to participate in the study. We further evaluated the efficacy and safety of arginine in treating PCOS by implementing the L-arginine clinical intervention protocol, and conducting post-intervention follow-up, efficacy evaluation, laboratory tests, and fecal sample 16S rRNA sequencing.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gut Microbiome | — | UNRESOLVED | — |
| L-arginine | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-arginine intervention | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- L-arginine intervention with 3g daily treatment for three months
- description
- L-arginine therapy
- interventionNames
- Drug: L-arginine intervention
Primary outcomes (1)
- measure
- menstrual frequency
- timeFrame
- Within 7 days of enrollment
- description
- number of menstruation in a year
Secondary outcomes (13)
- measure
- Homeostasis model assessment of insulin resistance
- timeFrame
- Within 7 days of enrollment
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * aged 18-45 years * Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003) Exclusion Criteria: * Pregnant women; * Hyperthyroidism or hypothyroidism * Severe liver and kidney function injury * Cancer patients; * Associated with severe infection, severe anemia, neutropenia and other blood system diseases; * Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes; * Patients with mental illness or intellectual disability; * Have a long history of taking hormone therapy; * Currently or recently participating in another clinical trial.
References
Publications (0)
Data not yet available